ArticleD-Cycloserine Augmentation of Cognitive-Behavioral Therapy for the Treatment of Anxiety DisordersJanicak, Philip G. MD, Editor; Dattilo, Natalie C. PhD; Manos, Rachel C. MS; Storch, Eric A. PhD; Goddard, Andrew W. MD Author Information Dr. Dattilo is Assistant Professor of Clinical Psychology in Clinical Psychiatry, Ms. Manos is Clinical Psychology Intern, and Dr. Goddard is Professor of Psychiatry and Director, Outpatient Psychiatry Clinic, University Hospital and IU Anxiety Research Clinic, Department of Psychiatry, Indiana University School of Medicine, 550 N University Blvd, Suite 3124, Indianapolis, IN 46202, E-mail: [email protected]; and Dr. Storch is All Children's Hospital Endowed Chair and Associate Professor, Departments of Pediatrics and Psychiatry, University of South Florida, Tampa, FL. Unless otherwise mentioned below, each faculty's spouse/life partner (if any) has no relevant relationships to disclose. Dr. Dattilo, Ms. Manos, and all staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity. Dr. Storch has disclosed that he is/was a consultant for Otsuka Pharmaceuticals and Prophase, Inc. Dr. Goddard has disclosed that he was a consultant/advisor for Bristol Meyers Squibb and Pfizer, and that he received grant funding from Janssen and Astra-Zeneca. The authors have disclosed that the use of D-cycloserine for treatment of anxiety disorders as discussed in this article has not been approved by the U.S. Food and Drug Administration. Lippincott CME Institute has identified and resolved all conflicts of interest related to this educational activity. Psychopharm Review: August 2011 - Volume 46 - Issue 8 - p 49-56 doi: 10.1097/01.PSYPHR.0000399653.06660.fa Buy CME Test Metrics © 2011 Lippincott Williams & Wilkins, Inc.